Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: John Curtis who wrote (1662)	4/28/2001 11:11:39 AM
From: Jibacoa	Respond to of 2344

John: IMNX: Seems to have good support at 14.75. It still has to deal with yesterday's intra-day double top at the 15.63 level and then with the April 19 H of 16.98. As you may recall the pretty good volume on that day (2,763,700)was mainly on the down-side(the stock closed at 15.75 not far from the intra-day L of 15.30) I still think IMNX has good potential while EMBREL sales keeps booming and the company can't keep up with the demand. I think it has a good chance of getting approved for psoriasis. As far as BIOM is concerned, I think we can expect good news coming at the ASCO meeting in San Francisco in early May. We can also expect an announcement about the "new partner" pretty soon and as the Summer gets closer the possibility of good results on the "Early Look" that may come in late August or September. The stock is maintaining the present up-trend that started at 9.30AM on April 24. The nearest resistance is yesterday's intra-day H of 7.90 which is also close to the Feb8-Feb.9 intra-day double top at 7.87 I am expecting for it, on this run, to test the January 29 intra-day H of 8.91 and may be the January 17 H of 9.25 After that the next hurdle will be the September H at 12.87 RAGL Bernard

To: John Curtis who wrote (1662)	5/1/2001 9:03:32 AM
From: Skipper	Read Replies (1) \| Respond to of 2344

Biomira Solidifies Patent Protection For MUC1 Cancer Antigen EDMONTON, May 1 /CNW/ - Biomira Inc. (Nasdaq: BIOM) (TSE: BRA) announced that on April 24, 2001, the Imperial Cancer Research Technology Limited (ICRT) of London, England, was issued a patent from the U.S. Patent and Trademark Office entitled: Antigen derived from the core protein of the human mammary epithelial mucin. (U.S. Patent number 6,222,020). This is a composition of matter patent for MUC1 covering the peptide used in Biomira's BLP25 liposomal cancer vaccine. "This patent is licensed by Biomira and represents a very important component in our coverage for the BLP25 vaccine program," said Alex McPherson, MD, PhD, President and CEO of Biomira. The ICRT U.S. patent will enjoy a 17-year term from issue and counterparts have already issued in Europe and Canada, while pending in Japan," he concluded. Biomira had previously acquired from the Imperial Cancer Research Technology Limited, the licensing arm of the Imperial Cancer Research Fund (ICRF), an exclusive worldwide license to ICRT's rights to a certain protein (MUC1 antigen) for in vivo, ex vivo and in vitro uses in the treatment and diagnosis of cancer. The MUC1 antigen is found on human breast, ovarian, colon and pancreatic cancer cells. Biomira and ICRT also entered into a second license agreement on November 5, 1999, which, among other things, granted Biomira an exclusive worldwide license of ICRT's MUC1 peptide patent rights for treatment and diagnosis of diseases other than cancer. As well, Biomira has an exclusive license (subject to certain rights of the United States government) from the Dana-Farber Cancer Institute, Inc. ("DFCI") of Boston, Massachusetts, in the United States for in vivo, ex vivo and in vitro uses in the treatment and prevention of cancer in humans. Biomira is currently recruiting patients into its BLP25 vaccine Phase IIb trial. The study is looking to recruit 166 patients at 14 evaluation sites, 10 in Canada and four in the United Kingdom. Patients will be eligible for the trial if they have had a good response to first line standard chemotherapy or if their disease is stable. The objective of the trial is to see if immunological responses previously shown in earlier trials translates to clinical benefit. Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. The Company has completed enrolment in its Phase III THERATOPE(R) vaccine trial for women with metastatic breast cancer. The trial enrolled 1,030 women in a multinational Phase III trial with THERATOPE(R) vaccine. The commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy. We are The Cancer Vaccine People(TM). This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing of clinical trials or the efficacy of products and the scope and validity of patent protection. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. -30- For further information: Biomira Company Contacts: Bill Wickson, Manager, Public Relations & Special Assistant, (780) 490-2818; Investor Relations, Jonathan Fassberg, The Trout Group, (212) 477-9007 x16, Media Contact: Brad Miles, BMC Communications, (212) 477-9007 x17; To request a free copy of this organization's annual report, please go to www.newswire.ca and click on reports@cnw.